Prostate cancer is the most common cancer among men in the U.S. and the second leading cause of cancer death. Yet, the traditional testing method, monitoring PSA, is just one piece in a complicated puzzle.
Knowing why a PSA is elevated, what the individual’s level of risk is, and if further testing is required create an important, full picture for predictive decision making.
MPS2 is a non-invasive urine test, offering a new level of simple, actionable, and data-driven decision making for both providers and patients.
You deserve the next generation in prostate cancer risk prediction for men’s health.
How It Works
Our Science. Clear Results. Your Decision.
A simple urine test that shines a highly sensitive light on a patient’s actual risk of prostate cancer when PSA is elevated. Our goal is to provide a solution with zero surprises for all involved.
Early Prostate Cancer Risk Assessment
One in eight men will receive a prostate cancer diagnosis during their lifetime. The good news? Survival is nearly 100% when diagnosed early and contained within the prostate. When it spreads, however, the five-year survival is just 31%.
Early detection is critical for you and your family.
You can avoid subjective, invasive tests and receive a highly accurate prostate cancer screening to assess your current risk.
MyProstateScore 2.0 can give you and your urologist accurate data to make a personalized healthcare decision for you.
Industry news, men’s health information, and expert prostate cancer and risk assessment research.
Five Myths About Prostate Cancer Everyone Should Know
Don’t believe everything you hear, especially when it comes [...]
Urology is Fun – Top Five Highlights from AUA23
Every year urologists from across the globe join together [...]
LynxDx President Steve Riggs Named Finalist for the Entrepreneur Of The Year® 2023 Michigan and Northwest Ohio
Entrepreneur Of The Year celebrates ambitious entrepreneurs who are building [...]